Paulette Bioulac‐Sage
YOU?
Author Swipe
View article: Clinical relevance of subtyping <i>CTNNB1</i>‐mutated hepatocellular adenomas: Different risk patterns according to the mutation type
Clinical relevance of subtyping <i>CTNNB1</i>‐mutated hepatocellular adenomas: Different risk patterns according to the mutation type Open
Background and Aims Beta‐catenin‐activated hepatocellular adenomas (b‐HCA) with exon 3 (ex3) non‐S45, ex3 S45 or ex7/8 mutations display different glutamine synthetase (GS)‐immunostaining patterns; the latter two show a GS‐positive/CD34‐ne…
View article: Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of β-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Author response: Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Author response: Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of β-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Reviewer #3 (Public Review): Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Reviewer #3 (Public Review): Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of β-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Reviewer #2 (Public Review): Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Reviewer #2 (Public Review): Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of β-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Reviewer #1 (Public Review): Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Reviewer #1 (Public Review): Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of β-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Emerging role of oncogenic ß-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of ß-catenin mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma
Loss of RND3/RHOE controls entosis through LAMP1 expression in hepatocellular carcinoma Open
Entosis is a process that leads to the formation of cell-in-cell structures commonly found in cancers. Here, we identified entosis in hepatocellular carcinoma and the loss of Rnd3 (also known as RhoE) as an efficient inducer of this mechan…
View article: Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma
Emerging role of oncogenic β-catenin in exosome biogenesis as a driver of immune escape in hepatocellular carcinoma Open
Immune checkpoint inhibitors have produced encouraging results in cancer patients. However, the majority of β-catenin-mutated tumors have been described as lacking immune infiltrates and resistant to immunotherapy. The mechanisms by which …
View article: Spatial characterisation of β-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim
Spatial characterisation of β-catenin-mutated hepatocellular adenoma subtypes by proteomic profiling of the tumour rim Open
Tumour heterogeneity was revealed in β-catenin-mutated hepatocellular adenomas (b-HCAs) via the differential expression of glutamine synthase at tumour rims. The combination of several spatial approaches (mass spectrometry imaging, genetic…
View article: Loss of<i>RND3/RHOE</i>controls entosis through<i>LAMP1</i>expression in hepatocellular carcinoma
Loss of<i>RND3/RHOE</i>controls entosis through<i>LAMP1</i>expression in hepatocellular carcinoma Open
Entosis is a process that leads to the formation of cell-in-cell structures commonly found in cancers. Here, we identified entosis in hepatocellular carcinoma and the loss of Rnd3 as an efficient inducer of this mechanism. We characterized…
View article: Supplementary Figure Legend from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Figure Legend from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 71K
View article: Supplementary Figure 1 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Figure 1 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 877K, Figure S1. (A) Quantification of Xbp1 mRNA splicing shown in Figure 2A. (B) Wild-type HepG2 cells were either not treated or treated with 10 μM Sorafenib for 2 h followed by staining for giantin, a Golgi complex marker, α-…
View article: Supplementary Methods from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Methods from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 81K
View article: Supplementary Figure 1 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Figure 1 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 877K, Figure S1. (A) Quantification of Xbp1 mRNA splicing shown in Figure 2A. (B) Wild-type HepG2 cells were either not treated or treated with 10 μM Sorafenib for 2 h followed by staining for giantin, a Golgi complex marker, α-…
View article: Data from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Data from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
The molecular mechanisms and cellular targets of sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma (HCC), remain to be fully characterized. Recent studies have shown that sorafenib induces tumor cell dea…
View article: Supplementary Table 1 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Table 1 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 52K, PCR primers used in this study
View article: Supplementary Figure 2 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Figure 2 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 510K, Figure S2. (A) HepG2 cells were either not treated or treated with 10 μM Sorafenib for 4 h, after which they were either fixed or Sorafenib removed from cells and fresh medium added for a further 2 h. Cells were then stain…
View article: Supplementary Figure Legend from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Figure Legend from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 71K
View article: Supplementary Table 2 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Table 2 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 36K, Quantification of eiF2α phosphorylation upon sorafenib treatment. X-ray film were quantified using scanning densitometry and data are represented as arbitrary units � SD.
View article: Data from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Data from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
The molecular mechanisms and cellular targets of sorafenib, a multikinase inhibitor used for the treatment of hepatocellular carcinoma (HCC), remain to be fully characterized. Recent studies have shown that sorafenib induces tumor cell dea…
View article: Supplementary Methods from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Methods from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 81K
View article: Supplementary Figure 2 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death
Supplementary Figure 2 from Sorafenib-Mediated Targeting of the AAA<sup>+</sup> ATPase p97/VCP Leads to Disruption of the Secretory Pathway, Endoplasmic Reticulum Stress, and Hepatocellular Cancer Cell Death Open
PDF file - 510K, Figure S2. (A) HepG2 cells were either not treated or treated with 10 μM Sorafenib for 4 h, after which they were either fixed or Sorafenib removed from cells and fresh medium added for a further 2 h. Cells were then stain…